Stock info Novonesis | Filter  Basic-Info

Stock: Novonesis (Danmark large caps), ISIN: DK0060336014

Last Price 439.90 Max Price 439.90
Min Price 439.90 1 Year return 0.00
Sector Basic Materials Subsector Chemicals
Annual report 2015

Loading...

Contact info:Street: Krogshoejvej 36Postbox: 2880City: BagsvaerdCountry: DenmarkPhone: 45-44-460000Website: www.novozymes.comCEO: Peder Holk NielsenCFO: Benny D. Loft

Sector Review Novonesis

Loading...
Year Turnover Total sector Market share
2019 1,925 647,449 0.30 %
2020 1,880 586,333 0.32 %
2021 2,010 763,024 0.26 %
2022 2,360 900,018 0.26 %
2023 2,402 783,668 0.31 %

Advice Novonesis

No Records Found




News Novonesis

Analysts expect over 2024 growing sales Novozymes

Tomorrow the Danish Novozymes will publish its past quarter figures. For this year the company from Bagsvaerd could earn a total revenue around 3.95 billion Danish Krone. This is according to the average of the analysts' estimates. The expected revenue would...

Analysts: Novozymes on steam for record sales

Tomorrow Novozymes will publish its past quarters results. Over the current book year the total revenu from the company based in will be 18.16 billion Danish Krone (consensus estimates). The expected revenue would be the highest in her history. This is slightly...

Analysts foresee record year for Novozymes

For this year the company, located in revenue will be around 18.17 billion Danish Krone. This is according to the average of the analysts' estimates. The expected revenue would be a record for the company. This is slightly more than 2022's revenue of 17.55 billion...

Analysts count on revenue increase Novozymes

Tomorrow the Danish Novozymes will report its past quarters results. Over the current book year the total revenue will be 14,79 billion Danish Krone (consensus estimates). This is slightly more than 2018's revenue of 14,39 billion Danish Krone. Historical revenues...

Analysts expect over 2018 decreasing revenue Novozymes

Tomorrow the Danish company Novozymes will publish its past quarters results. For this year Novozymes's revenue will be around 14,49 billion Danish Krone. This is according to the average of the analysts' estimates. This is slightly lower than 2017's revenue of...

Annual reports Novonesis

2017 2018 2019 2020 2021

Profile Novonesis

Novozymes

(DK0060336014)/ NZYM B

The company's head quarter is located in Bagsvaerd. The company mostly operates in the chemical sector. Peder Holk Nielsen is the CEO of the company. Benny D. Loft leads the company as CFO. The global chemical companies gained around 72 percent over the period 2006-2016. Measured since 2011 the sector is 20 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 72 percent.

The past year was a good investment year for Novozymes investors

Over the period from December 2015 till December 2016 the stock lost around 26 percent. Over the period 2011-2016 the stock rose a massive 39,66 percent. Novozymes's revenues between 2011 and 2015 were relatively stable and moved between 2,76 billion euros and 3,34 billion euros. Novozymes's net incomes between 2011 and 2015 were very volatile and moved between 1,83 billion euros and 2,83 billion euros.

Novozymes paid out dividends in the past 5 years. Novozymes's dividend return over the period 2011 - 2015 was around 13,1 percent per year. Over the past 5 years Novozymes raised her dividends share each year. So we could call Novozymes a kind of dividend aristocrat.

At the end of 2015 around 6079 thousand people were on Novozymes' payroll.

Novozymes' balance mostly consists of equity

At the end of 2015 the Danish company's balance sheet was worth 17,79 billion euros. At the end of 2015 the total debt positon equaled 6,21 billion euros. This is around 34,91 percent of the total balance sheet. At the end of 2016 the Danish company was traded with a price/earnings-ratio of around 27. So investors paid 27 times the company's 2015's EPS. Based on the classical stock valuation theories the Danish stock can be seen as a value stock.

At the end of 2015 the chemical company's market capitalization (the number of shares times the market price) equaled around 101,88 billion euros. At the end of 2015 the Danish company had around 309,38 million stocks listed.

All the company's financial reports are available here. More information about Novozymes can be found it's website. .


Results Novonesis

Results
2015
2016
2017
2018
2019
2020
Revenue
1,877
1,899
1,953
1,931
1,925
1,880
Costs
1,499
1,490
1,534
1,499
1,503
1,501
Profit
378
409
419
432
422
379
Margin of profit
20.14
21.54
21.45
22.37
21.92
20.16
ROI
24.37
25.90
27.71
28.24
27.49
25.12

Balance Novonesis

Balance
2015
2016
2017
2018
2019
2020
Equity
1,551
1,579
1,512
1,530
1,535
1,509
Debt
832
933
956
1,107
1,201
1,247
Total assets
2,383
2,512
2,468
2,637
2,736
2,756
Solvency
65.09
62.86
61.26
58.02
56.10
54.75
Cash
115
109
87
98
97
174
Cashflow
447
515
546
493
428
584
Employees
6,485
0
0
0
0
Revenue per employee
0.29
0.0
0.0
0.0
0.0
Cashflow / Debt
0.54
0.55
0.57
0.45
0.36
0.47

Details Novonesis

Details
2016
2017
2018
2019
2020
Price
330.60
243.50
354.50
290.90
326.00
Eps
1.00
1.00
1.00
1.00
1.00
Price/earnings-ratio
330.60
243.50
354.50
290.90
439.90
Dividend
0.0
0.0
0.0
0.0
Dividend %
0.00 %
0.00 %
0.00 %
0.00 %
Payout %
0.0
0.0
0.0
0.0
Book value
6.47
6.32
6.54
6.74
6.69
Market to book
0.02
0.03
0.02
0.02
0.02
Cashflow per stock
2.11
2.28
2.11
1.88
2.59
Stocks
244
239
234
228
226
Market Cap
80.624.96
58.246.49
82.900.18
66.206.80
99.233.52

Dividend Novonesis


Price info Novonesis

Date
Price
23 Jul 2025
439.90